Ann: PTX-200 Breast Cancer Trial Progresses, page-6

Any company can 'get to the market' at different stages of their product of offer.
Some gain commercialisation at even the exploratory stages, other fail to meet criterion even after phase 3.
Different sciences or offers reflect different contracts by big pharma all encompassed by timing factors., for example, if they already have a candidate in place within patented timeframes, why invest in a similar product again..
Remembering that, if big pharma are to take a chance, its often calculated to bring in big money for them, often with as little risk as possible which makes perfect sense.
Back to ptx; 2 plantinum drugs performing well on potency efficacy with low toxucity, low share registry, accelerated progress towards phase 2, exclusive recent completion if a team, funded with grants and by it's shareholders.
In my opinion only, undervalued and willing to hold and accumulate.
If all goes well, very rare in the bio sector, we could be a divident share receiver before 2020, even if another cr is needed, but one day at a time.
GLTAH